Ligand Pharmaceuticals (LGND) Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, community ranking, risk and valuation.

Do institutionals and insiders hold more shares of LGND or RGEN?

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 5.9% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 1.2% of Repligen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has preferable valuation and earnings, LGND or RGEN?

Ligand Pharmaceuticals has higher earnings, but lower revenue than Repligen. Repligen is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$152.42M	14.21	$52.15M	$2.51	45.67
Repligen	$639.92M	12.65	$35.60M	-$0.37	-390.43

Which has more volatility and risk, LGND or RGEN?

Ligand Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Repligen has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.

Is LGND or RGEN more profitable?

Ligand Pharmaceuticals has a net margin of 29.68% compared to Repligen's net margin of -3.36%. Ligand Pharmaceuticals' return on equity of 4.95% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	29.68%	4.95%	4.39%
Repligen	-3.36%	3.90%	2.72%

Do analysts prefer LGND or RGEN?

Ligand Pharmaceuticals currently has a consensus target price of $147.00, suggesting a potential upside of 28.23%. Repligen has a consensus target price of $185.20, suggesting a potential upside of 28.20%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Ligand Pharmaceuticals is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Repligen	0 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.62

Does the MarketBeat Community believe in LGND or RGEN?

Ligand Pharmaceuticals received 142 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 70.73% of users gave Ligand Pharmaceuticals an outperform vote while only 67.60% of users gave Repligen an outperform vote.

Company	Underperform	Outperform
Ligand Pharmaceuticals	Outperform Votes 551 70.73%	Underperform Votes 228 29.27%
Repligen	Outperform Votes 409 67.60%	Underperform Votes 196 32.40%

Does the media prefer LGND or RGEN?

In the previous week, Ligand Pharmaceuticals and Ligand Pharmaceuticals both had 22 articles in the media. Ligand Pharmaceuticals' average media sentiment score of 0.93 beat Repligen's score of 0.62 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	6 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ligand Pharmaceuticals beats Repligen on 14 of the 17 factors compared between the two stocks.